Clinical Relevance of Anti-Neutrophil Cytoplasm Antibody (ANCA)in Hospitalized Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01238003

Enrollment

380

Registered

2010-11-10

Start date

2010-12-31

Completion date

2011-12-31

Last updated

2010-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ANCA-related Vasculitis

Brief summary

Laboratory testing of Anti-Neutrophil Cytoplasm Antibody (ANCA) is used to confirm diagnosis of patients who have a high level of suspicion for ANCA-related vasculitis. In these patients the specificity and sensitivity to the ANCA test is very high. This study hopes to prove that when this lab test is performed on blood of patients who do not have a high level of suspicion for ANCA-related vasculitis, the sensitivity and specificity is reduced and there are many false positive results. Because of this, it should not be used as a screening test for a more general patient population.

Interventions

OTHERInterpretation of blood test results

Interpretation of blood test results

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Blood samples sent for ANCA lab test

Exclusion criteria

* Patients with ANCA vasculitis * Patients with known malignancy

Design outcomes

Primary

Measure	Time frame
Mostly negative lab results	One year

Countries

Israel

Contacts

Primary ContactNina Avshovich, MD

ninaa@hy.health.gov.il972-52-5566049

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026